Research Projects & Grants

For Profit Organization

  • A 24 month, multicenter,randomized, open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibitor in denovo renal transplant- advancing renal transplant efficacy and safety outcomes with an eveRolimus- based regimen (TRANSFORM, Jan 2015), Role: Investigator, Novartis Pharmaceuticals Corporation, (02/2018 - 02/2019) Status: Completed
  • A randomized, global, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of once-daily oral avatrombopag for the treatment of adults with thrombocytopenia associated with liver disease prior to an elective procedure (Eisai, May 2015), Role: Investigator, Eisai Medical Research, Inc., (08/2016 - 08/2017) Status: Completed
  • A phase 3, double-blind, double-dummy, multi-center, prospective, randomized study of the efficacy and safety of LCP-Tacro™ tablets, once daily, compared to Prograf® capsules, twice daily, in combination with mycophenolate mofetil for the prevention of acute allograft rejection in De Novo adult kidney transplant recipients (protocol LCP-Tacro 3002 version 3.0 September 30, 2010), Role: Investigator, LifeCycle Pharma A/S, (10/2013 - 10/2014) Status: Completed
  • A phase 2, randomized, open-label, parallel group, multi-center study to assess the safety and efficacy of alefacept in de novo kidney transplant recipients, Role: Investigator, Astellas Pharma US, Inc., (01/2011 - 01/2012) Status: Completed
  • A Phase III, randomized, open-label, comparative, multi-center study to assess the safety and efficacy of Prograf (tacrolimus)/MMF, modified release (MR) tacrolimus/MMF and neoral (cyclosporine)/MMF in de novo kidney transplant recipients, Role: Investigator, Fujisawa, (02/2009 - 02/2010) Status: Completed
  • A 24-month, multicenter, randomized, open-label non-inferiority study of efficacy and safety comparing concentration-controlled certican in two doses (1.5 and 3.0 g/day starting doses) with reduced neoral versus 1.44g myfortic with standard dose neoral in de novo renal transplant recipients., Role: Investigator, Novartis Pharmaceuticals Corporation, (10/2006 - 10/2007) Status: Completed
  • A three-month open-label, two-cohort study to investigate the safety and tolerability of myfortic in combination with neoral and tacrolimus in renal transplant recipients with GI intolerance, Role: Investigator, Novartis Pharmaceuticals Corporation, (11/2005 - 11/2006) Status: Completed
  • A one-year, multicenter, partially blinded, double-dummy, randomized study to evaluate the efficacy and safety of FTY720 combined with reduced-dose or full-dose Neoral and corticosteroids versus mycophenolate mofetil (MMF, CellCept) combined with full-dose Neoral and corticosteroids, in de novo adult renal transplant recipients, Role: Investigator, Novartis Pharmaceuticals Corporation, (06/2004 - 10/2004) Status: Completed
  • An open-label, multicenter study to further characterize the clinical utility and safety of rapamune and cyclosporine combination treatment in de novo renal allograft recipients (Project #0468E1, dated 01/12/99)., Role: Investigator, Wyeth-Ayerst Laboratories, (04/2000 - 04/2001) Status: Completed
  • A randomized, multicenter, comparative trial of prograf (Tacrolimus) in combination with rapamune (Sirolimus) or cellcept (Mycophenolate Mofetil) after kidney transplant, Role: Investigator, Fujisawa, Status: Completed
  • A randomized comparative trial of the effects of antilymphocyte induction on the tacrolimus plus mycophenolate mofetil maintenance immunosuppression after simultaneous kidney/pancreas transplantation, Role: Investigator, Fujisawa, Status: Completed

Internal

  • The role of B cells in kidney allograft dysfunction (B cell 3/1/2014), Role: Investigator, LLU Transplantation Institute, (06/2022 - 06/2023) Status: Completed
  • Retrospective study of kidney transplant patients using immune cell function (immuknow) testing., Role: Investigator, LLU Transplantation Institute, (01/2009 - 01/2010) Status: Completed
  • Clinical outcomes of induction therapies in renal transplant patients, Role: Investigator, LLU Transplantation Institute, (12/2007 - 12/2015) Status: Completed
  • A restrospective study evaluating cytomegalovirus prophylaxis in kidney and liver transplant recipients., Role: Investigator, LLU Transplantation Institute, (08/2004) Status: Completed
  • Use of Basiliximab with Mycophenolate Mofetil in kidney transplantation, Role: Investigator, LLU Transplantation Institute, (04/2003) Status: Completed

Non-Profit Organization

  • Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppresion Trial (BENEFIT), Role: Investigator, Bristol-Myers Squibb Foundation, Inc., (01/2010 - 01/2011) Status: Completed
  • Belatacept evaluation of nephroprotection and efficacy as first-line immunosuppression trial - extended criteria donors, Role: Investigator, Bristol-Myers Squibb Foundation, Inc., (06/2006 - 06/2007) Status: Completed